This bill reauthorizes through FY2027 the Food and Drug Administration's Critical Path Public-Private Partnerships, which support medical product innovation, development, and safety.
Actions
May 5, 2022
Introduced in Senate
May 5, 2022
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.